<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626114</url>
  </required_header>
  <id_info>
    <org_study_id>GR44251</org_study_id>
    <nct_id>NCT05626114</nct_id>
  </id_info>
  <brief_title>A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration</brief_title>
  <official_title>A Phase IIa, Multicenter, Open-Label, Single-Arm Study To Optimize Subretinal Surgical Delivery And To Evaluate Safety And Activity Of Opregen In Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the success and safety of subretinal surgical delivery as well as&#xD;
      the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to&#xD;
      age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless&#xD;
      otherwise indicated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2023</start_date>
  <completion_date type="Anticipated">September 15, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2029</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Subretinal Surgical Delivery of OpRegen to Target Regions</measure>
    <time_frame>3 months post surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Procedure-related Adverse Events at 3 Months Following Surgery</measure>
    <time_frame>3 months post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Qualitative Improvement in Retinal Structure, as Determined by OCT Imaging Within 3 Months Following Surgery</measure>
    <time_frame>3 months post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>OpRegen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OpRegen</intervention_name>
    <description>OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space</description>
    <arm_group_label>OpRegen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care&#xD;
&#xD;
          -  Diagnosis of GA secondary to AMD&#xD;
&#xD;
          -  BCVA score &gt;/= 35 letters and &lt;/= 60 letters in the study eye as assessed by ETDRS&#xD;
&#xD;
          -  Pseudophakic (study eye)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  History of cognitive impairment or dementia&#xD;
&#xD;
          -  Any type of systemic disease or its treatment, in the opinion of the investigator,&#xD;
             including any medical conditions that could be expected to progress, recur, or change&#xD;
             to such an extent that it may bias the assessment of the clinical status of the&#xD;
             patient to a significant degree or put the patient at special risk&#xD;
&#xD;
        Ocular Exclusion Criteria for Study Eye:&#xD;
&#xD;
          -  Any current or history of ocular disease other than GA that may confound assessment of&#xD;
             the macula&#xD;
&#xD;
          -  History of retinal detachment&#xD;
&#xD;
          -  History of vitrectomy, glaucoma-filtering surgery, or corneal transplant&#xD;
&#xD;
          -  Uncontrolled glaucoma or advanced glaucoma&#xD;
&#xD;
          -  Any cataract surgery or intraocular surgery within 3 months prior to subretinal&#xD;
             surgical delivery of OpRegen&#xD;
&#xD;
          -  History of other ocular or intraocular conditions that contraindicate the use of an&#xD;
             investigational drug or may affect interpretation of the study results or may render&#xD;
             the patient at high risk for treatment complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GR44251 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>April 12, 2023</last_update_submitted>
  <last_update_submitted_qc>April 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geographic Atrophy secondary to Age-related Macular Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

